inhalable insulin pfizer’s exubera (Pfizer Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Pfizer Inc inhalable insulin pfizer’s exubera
Inhalable Insulin Pfizer’s Exubera, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/exubera+pfizer/inhaled+insulin+exubera/pm33536635-255-0-2
Average 90 stars, based on 1 article reviews

inhalable insulin pfizer’s exubera - by Bioz Stars, 2026-11

90/100 stars

Images

Lyophilization:

Article Title: Cryomilled electrospun nanofiber mats containing d-mannitol exhibit suitable for aerosol delivery of proteins.
Article Snippet: Dry powder inhalers (DPIs) are the first choice for inhalation drug development.. However, some conventional DPI formulation processes require heating, which may damage high molecular weight drugs such as proteins and nucleic acids.. In this study, we propose a novel DPI preparation process that avoids the use of heat.

Food & Beverages:

Article Title: A Review on Micro and Nanoengineering in Powder-Based Pulmonary Drug Delivery.
Article Snippet: .. In fact, after the release of the first inhalable insulin product Exubera® (Pfizer, NY, USA) in 2006, Food and Drug Administration (FDA) approved in 2015 another insulin product for inhalation (Afrezza®, Mannkind, CA, USA) (Fleming et al., 2015) based on the innovative Technosphere® technology (MannKind, CA, USA) (Jain et al., 2020; Newman, 2017). ..

other:

Article Title: Peptide pharmaceuticals for insulin resistance
Article Snippet: Lyophilized powders, especially glassy particles, containing the active peptide and an excipient are useful for delivery to the lung with good bioavailability, for example, see Exubera® (inhaled insulin by Pfizer and Aventis Pharmaceuticals Inc.).

Article Title: Mapping the evolution of inhaled drug delivery research: Trends, collaborations, and emerging frontiers.
Article Snippet: 1 Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 South Daxuecheng Road, Chongqing 401331, PR China 2 Chongqing Key Laboratory of High Active Traditional Chinese Drug Delivery System, Chongqing Engineering Research Center of Pharmaceutical Sciences, Chongqing Medical and Pharmaceutical College, Chongqing 404120, PR China 3 Sichuan Kelun Pharmaceutical Research Institute Co. Ltd, Chengdu 611138, Sichuan, PR China Department of Dermatology, The First Affiliated Hospital, Army Medical University, 30 Gaotanyan Street, Chongqing 400038, PR China research and teaching are mainly focused on (academic) drug delivery technology, designing of protein drug delivery vector, sustained and controlled release, and inhaled drug delivery. ted P c

Article Title: 100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future
Article Snippet: The first non-injectable insulin administration method to hit the market was inhaled insulin, marketed in 2006 by Pfizer under the name Exubera; however, it was quickly withdrawn from the market due to its adverse effects, mainly coughing and alterations of lung function [ , ].

Article Title: Exploring Intestinal Surface Receptors in Oral Nanoinsulin Delivery.
Article Snippet: In 2006, Pfizer launched Exubera, an inhaled insulin (Wong et al., 2016).

Article Title: Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
Article Snippet: The first inhaled insulin, Exubera by Pfizer, was approved by the FDA in 2006 .

Recombinant:

Article Title: Use of ultrarapid acting insulin
Article Snippet: .. The experiments were conducted to identify the effect of an ultrarapid acting insulin, specifically a formuslation for inhalation comprising insulin-FDKP, when compared to subcutaneously administered insulin lispro (lispro, HUMALOG® , Eli Lilly & Co.) and an inhaled recombinant human insulin (EXUBERA®, Pfizer Inc.) on endogenous glucose production after a meal challenge and during a euglycemic glucose clamp procedure in subjects with type 2 diabetes. .. The insulin-FDKP formulation is administered to the subjects by oral inhalation using a MEDTONE® dry powder inhaler (MannKind Corp.).

Review